BCC 2023 | Why are we conducting clinical trials in countries that are unlikely to afford novel drugs?

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, delves into a critical topic that affects not only the medical community but also the global population. Her lecture during the St. Gallen International Breast Cancer Consensus Meeting, centered on the rationale behind conducting clinical trials in low-resource countries, sheds light on the importance of equitable access to innovative drugs for all patients regardless of socioeconomic status. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.